GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CTT Pharmaceutical Holdings Inc (OTCPK:CTTH) » Definitions » Debt-to-EBITDA

CTT Pharmaceutical Holdings (CTT Pharmaceutical Holdings) Debt-to-EBITDA : -0.01 (As of Jun. 2018)


View and export this data going back to . Start your Free Trial

What is CTT Pharmaceutical Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

CTT Pharmaceutical Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2018 was $0.00 Mil. CTT Pharmaceutical Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2018 was $0.04 Mil. CTT Pharmaceutical Holdings's annualized EBITDA for the quarter that ended in Jun. 2018 was $-4.36 Mil. CTT Pharmaceutical Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2018 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for CTT Pharmaceutical Holdings's Debt-to-EBITDA or its related term are showing as below:

CTTH's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.7
* Ranked among companies with meaningful Debt-to-EBITDA only.

CTT Pharmaceutical Holdings Debt-to-EBITDA Historical Data

The historical data trend for CTT Pharmaceutical Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTT Pharmaceutical Holdings Debt-to-EBITDA Chart

CTT Pharmaceutical Holdings Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CTT Pharmaceutical Holdings Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Mar17 Jun17 Mar18 Jun18
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -0.01

Competitive Comparison of CTT Pharmaceutical Holdings's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, CTT Pharmaceutical Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CTT Pharmaceutical Holdings's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CTT Pharmaceutical Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CTT Pharmaceutical Holdings's Debt-to-EBITDA falls into.



CTT Pharmaceutical Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CTT Pharmaceutical Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2015 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -1.446
=0.00

CTT Pharmaceutical Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2018 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0.04) / -4.36
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2018) EBITDA data.


CTT Pharmaceutical Holdings  (OTCPK:CTTH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


CTT Pharmaceutical Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CTT Pharmaceutical Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CTT Pharmaceutical Holdings (CTT Pharmaceutical Holdings) Business Description

Traded in Other Exchanges
N/A
Address
1100 – 1111 Melville Street, Vancouver, BC, CAN, V6E 3V6
CTT Pharmaceutical Holdings Inc is a development stage company specializing in drug delivery systems technology within the pharmaceutical industry. It focuses on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The thin wafers are infused with both natural and synthetic cannabis extracts to deliver treatment as an alternative to smoking and ingestion. Its products include Medwafe, Cannawafe, Vetwafe, and others.
Executives
Albert C Zapanta director PO BOX 2020, SPRINGDALE AR 72765
William Thomson director 390 BAY ST, SUITE 1102, TORONTO ONTARIO A6 M5H 2Y2